Hamburger

Call: 1-202-476-5000

   
 
Pressroom
News Releases
Archives
Children's In The News
Video Gallery
Watch Us Grow
Press Kit
Media Sign Up
Contact Us
 
 
Email this page Email This Page
Print this page Print This Page
 

  Join Us On:
  Follow Children's on Facebook  Facebook
  Follow Children's on Twitter  Twitter
  Watch Children's on YouTube  YouTube
 
 
 
     
  Results of New Clinical Trial Demonstrate How Personalized Medicine May Drastically Change the Treatment of Genetic Disorders
December 27, 2007

For Immediate Release: December 27, 2007

Contact: Jennifer Leischer, 202-476-4500

Leading geneticist says efforts underway in treating genetic diseases present challenges for how drugs are approved and delivered to accommodate major technology advances.

Washington, DC—One of the nation’s pre-eminent genetic researchers, Eric Hoffman, PhD, of Children’s Research Institute at Children’s National Medical Center, predicts that in relatively short order, medicine’s next innovation--individualized molecular therapies—will have the unprecedented ability to treat muscular dystrophies, and other disorders.

In the latest edition of the New England Journal of Medicine, Dr. Hoffman posits that the results of a small clinical trial involving a new treatment for Duchenne muscular dystrophy provides a proof-of-principle for personalized molecular medicine. Practical implementation of the ‘exon-skipping’ approach described in the co-published report of vanDeutekom et al. will require advances in systemic administration of large amounts of customized DNA-like drugs, and proof that long-term delivery is not toxic. However, these advances are likely to come in short order, with the oversight and regulations of the FDA critical for appropriate labeling and marketing of such personalized molecular target drugs.

Though this particular treatment remains in its early stages, within the foreseeable future the now-standard Phase I, II, and III pathway to drug approvals may need to be re-evaluated.

How can DNA-like drugs specific to a single patient’s mutation go through the existing approval process? Are the current standards of rodent and monkey toxicity studies relevant and appropriate for DNA-like drugs, when the animals do not have the same DNA target (or off-target) sequences as humans? These and other questions are certain to pose exciting challenges to both the approval and marketing processes of drugs.

The study featured in the latest edition of the New England Journal of Medicine, involves application of a nucleic acid drug called PRO051. It shows some success at restoring the expression of the specific protein--dystrophin, that is linked to healthy muscle tissue. This approach was shown to reactivate dystrophin protein production in small areas of muscle tissue at the injection site of muscular dystrophy patients.

“Dozens of specific sequences will be required for effectively treating the majority of patients with Duchenne’s muscular dystrophy,” writes Dr. Hoffman. “But in order to realize the promise of personalized molecular medicine in muscular dystrophies and, ultimately, other disorders, it will be important to re-evaluate current measures of toxicity, efficacy, and marketing that ensure both safety for the patient, as well as rapid development and distribution of life-saving drugs.”
Dr. Hoffman envisions that some parts of the approval process may be developed for DNA-like molecular medicine as a ‘class’ of drugs, rather than individual testing of hundreds of different sequences.

“The patients and their families are crossing their fingers that the drug’s overall chemistry can be shown to be safe,” he says.

About Duchenne muscular dystrophy

Duchenne muscular dystrophy (DMD) affects about 1 in 3,500 boys of all races and ethnicities born in the U.S. and around the world. DMD has the greatest annual per-person cost for outpatient rehabilitation treatment of all neuromuscular disorders. The combination of the disease's prevalence, seriousness, unpredictable occurrence, cross-cultural presentation and combined emotional and financial expense make DMD a significant public health concern.

About Eric P. Hoffman, PhD

Dr. Hoffman is a world-renowned human geneticist, who is the Director of the Research Center for Genetic Medicine, a James Clark Professor of Pediatrics at Children’s National Medical Center and George Washington University in Washington DC. The Center has integrated state-of-the-art basic genetics research (genome, transcriptome, and proteome), with an international clinical trial network, and ethics research. He has one of the largest and most diverse portfolios of research and foundation funding world-wide, with nearly $9 million per year in support on topics ranging from muscular dystrophy, medical rehabilitation studies, type 2 diabetes, and asthma. He leads a team of about 100 researchers dedicated to the study of translational research and therapeutics in pediatric medicine. He has over 300 publications, some of which are among the most cited.

# # #

Children's National Medical Center, located in Washington, DC, is a proven leader in the development of innovative new treatments for childhood illness and injury. Consistently ranked among the top pediatric hospitals in America, Children’s has been serving the nation's children for more than 135 years. Children’s National is proudly ranked among the best pediatric hospitals in America by US News & World Report and the Leapfrog Group. For more information, visit www.dcchildrens.com. Children’s Research Institute, the academic arm of Children’s National Medical Center, encompasses the translational, clinical and community research efforts of the institution. Visit our web site at www.childrensnational.org.